Review of the reported measures of clinical validity and clinical utility as arguments for the implementation of pharmacogenetic testing: A case study of statin-induced muscle toxicity

Marleen E. Jansen, T. Rigter, W. Rodenburg, T. M.C. Fleur, E. J.F. Houwink, M. Weda, Martina C. Cornel

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Advances from pharmacogenetics (PGx) have not been implemented into health care to the expected extent. One gap that will be addressed in this study is a lack of reporting on clinical validity and clinical utility of PGx-tests. A systematic review of current reporting in scientific literature was conducted on publications addressing PGx in the context of statins and muscle toxicity. Eighty-nine publications were included and information was selected on reported measures of effect, arguments, and accompanying conclusions. Most authors report associations to quantify the relationship between a genetic variation an outcome, such as adverse drug responses. Conclusions on the implementation of a PGx-test are generally based on these associations, without explicit mention of other measures relevant to evaluate the test's clinical validity and clinical utility. To gain insight in the clinical impact and select useful tests, additional outcomes are needed to estimate the clinical validity and utility, such as cost-effectiveness.

Original languageEnglish
Article number555
JournalFrontiers in Pharmacology
Volume8
Issue numberAUG
DOIs
Publication statusPublished - 23 Aug 2017

Cite this

@article{1cb7bf3370664d0384bd2c1ad3158681,
title = "Review of the reported measures of clinical validity and clinical utility as arguments for the implementation of pharmacogenetic testing: A case study of statin-induced muscle toxicity",
abstract = "Advances from pharmacogenetics (PGx) have not been implemented into health care to the expected extent. One gap that will be addressed in this study is a lack of reporting on clinical validity and clinical utility of PGx-tests. A systematic review of current reporting in scientific literature was conducted on publications addressing PGx in the context of statins and muscle toxicity. Eighty-nine publications were included and information was selected on reported measures of effect, arguments, and accompanying conclusions. Most authors report associations to quantify the relationship between a genetic variation an outcome, such as adverse drug responses. Conclusions on the implementation of a PGx-test are generally based on these associations, without explicit mention of other measures relevant to evaluate the test's clinical validity and clinical utility. To gain insight in the clinical impact and select useful tests, additional outcomes are needed to estimate the clinical validity and utility, such as cost-effectiveness.",
keywords = "Clinical utility, Clinical validity, Pharmacogenetics, Statins, Translation",
author = "Jansen, {Marleen E.} and T. Rigter and W. Rodenburg and Fleur, {T. M.C.} and Houwink, {E. J.F.} and M. Weda and Cornel, {Martina C.}",
year = "2017",
month = "8",
day = "23",
doi = "10.3389/fphar.2017.00555",
language = "English",
volume = "8",
journal = "Frontiers in Pharmacology",
issn = "1663-9812",
publisher = "Frontiers Media S.A.",
number = "AUG",

}

Review of the reported measures of clinical validity and clinical utility as arguments for the implementation of pharmacogenetic testing : A case study of statin-induced muscle toxicity. / Jansen, Marleen E.; Rigter, T.; Rodenburg, W.; Fleur, T. M.C.; Houwink, E. J.F.; Weda, M.; Cornel, Martina C.

In: Frontiers in Pharmacology, Vol. 8, No. AUG, 555, 23.08.2017.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Review of the reported measures of clinical validity and clinical utility as arguments for the implementation of pharmacogenetic testing

T2 - A case study of statin-induced muscle toxicity

AU - Jansen, Marleen E.

AU - Rigter, T.

AU - Rodenburg, W.

AU - Fleur, T. M.C.

AU - Houwink, E. J.F.

AU - Weda, M.

AU - Cornel, Martina C.

PY - 2017/8/23

Y1 - 2017/8/23

N2 - Advances from pharmacogenetics (PGx) have not been implemented into health care to the expected extent. One gap that will be addressed in this study is a lack of reporting on clinical validity and clinical utility of PGx-tests. A systematic review of current reporting in scientific literature was conducted on publications addressing PGx in the context of statins and muscle toxicity. Eighty-nine publications were included and information was selected on reported measures of effect, arguments, and accompanying conclusions. Most authors report associations to quantify the relationship between a genetic variation an outcome, such as adverse drug responses. Conclusions on the implementation of a PGx-test are generally based on these associations, without explicit mention of other measures relevant to evaluate the test's clinical validity and clinical utility. To gain insight in the clinical impact and select useful tests, additional outcomes are needed to estimate the clinical validity and utility, such as cost-effectiveness.

AB - Advances from pharmacogenetics (PGx) have not been implemented into health care to the expected extent. One gap that will be addressed in this study is a lack of reporting on clinical validity and clinical utility of PGx-tests. A systematic review of current reporting in scientific literature was conducted on publications addressing PGx in the context of statins and muscle toxicity. Eighty-nine publications were included and information was selected on reported measures of effect, arguments, and accompanying conclusions. Most authors report associations to quantify the relationship between a genetic variation an outcome, such as adverse drug responses. Conclusions on the implementation of a PGx-test are generally based on these associations, without explicit mention of other measures relevant to evaluate the test's clinical validity and clinical utility. To gain insight in the clinical impact and select useful tests, additional outcomes are needed to estimate the clinical validity and utility, such as cost-effectiveness.

KW - Clinical utility

KW - Clinical validity

KW - Pharmacogenetics

KW - Statins

KW - Translation

UR - http://www.scopus.com/inward/record.url?scp=85028079494&partnerID=8YFLogxK

U2 - 10.3389/fphar.2017.00555

DO - 10.3389/fphar.2017.00555

M3 - Article

VL - 8

JO - Frontiers in Pharmacology

JF - Frontiers in Pharmacology

SN - 1663-9812

IS - AUG

M1 - 555

ER -